Cadrenal Therapeutics (CVKD) Company Report

Cadrenal Therapeutics (CVKD) is advancing three programs to address critical gaps in anticoagulation for rare and high-risk patients.
The pipeline includes tecarfarin (Phase 3 for end-stage renal disease with atrial fibrillation or implanted left ventricular assist devices), VLX-1005 (completed Phase 2 for Heparin-induced thrombocytopenia (HIT)), and Fruinexian (Phase 2 for cardiovascular surgery).
VLX-1005, which holds Orphan Drug and Fast Track designations, is identified as the primary value inflection driver over the next three to five years.
Upcoming milestones for VLX-1005 include the analysis and publication of Phase 2 data and FDA interaction later this quarter (Q1 2026).
The company projects a combined $3 billion in peak annual revenue opportunity across its targeted indications.

Jan 15, 2026, 9:30 PM

Cadrenal Therapeutics Discusses Anticoagulation Strategy and Program Updates

CVKD

New Projects/Investments

M&A

Cadrenal Therapeutics focuses on bridging critical gaps in anticoagulation for rare and high-risk patients, addressing areas where prevalent direct oral anticoagulants (DOACs) and warfarin are either contraindicated or not used.
The company has three key programs: Tecarfarin (Phase 3, with orphan drug designations for end-stage renal disease with AFib and patients with implanted left ventricular assist devices), VLX-1005 (recently acquired, completed Phase 2 for Heparin-Induced Thrombocytopenia (HIT), holding Orphan Drug and Fast Track designations), and Fruinexian (a Phase 2 candidate for cardiovascular surgery).
VLX-1005 is considered the primary value inflection driver over the next three to five years, with upcoming milestones including Phase 2 data analysis and publication, and FDA interaction later this quarter (Q1 2026).
The targeted indications represent a significant market opportunity, with 50,000 confirmed new HIT patients annually in the U.S. alone and a combined $3 billion in peak annual revenue opportunity across Cadrenal's programs.

Jan 15, 2026, 9:30 PM

Cadrenal Therapeutics Highlights VLX-1005 as Potential HIT Treatment and Plans for Phase 3 Study

CVKD

New Projects/Investments

M&A

Cadrenal Therapeutics highlighted the significant unmet medical need in heparin-induced thrombocytopenia (HIT) and the promise of its recently acquired investigational drug candidate, VLX-1005, as a potential new treatment option.
VLX-1005, acquired in December 2025, is the first and only potent, highly selective 12-LOX inhibitor in clinical testing.
Emerging data from a recent Phase 2 clinical trial suggest VLX-1005 may reduce thrombotic complications in suspected HIT, and Cadrenal plans to engage with the FDA to discuss the design of a potential pivotal Phase 3 registration study for VLX-1005 in HIT.
VLX-1005 has received Orphan Drug Designation and Fast Track designation from the FDA, as well as orphan drug status from the European Medicines Agency.

Jan 12, 2026, 1:00 PM

Cadrenal Therapeutics Updates on Tecarfarin and Fornixum Clinical Development

CVKD

New Projects/Investments

M&A

Cadrenal Therapeutics is developing novel anticoagulation drugs, Tecarfarin and Fornixum, to address gaps in high-risk and orphan indications, representing a $2 billion U.S. market.
Tecarfarin, a next-generation vitamin K antagonist, holds orphan drug and/or fast track designation for end-stage kidney disease (ESKD) and atrial fibrillation (AFib), and left ventricular assist devices (LVADs).
A Phase 2 study for Tecarfarin in dialysis patients is scheduled to begin enrollment in Q1 2026, with a registration study planned for 2027 and an additional LVAD Phase 2 study targeted for later in 2026.
The company recently acquired Fornixum, an intravenous factor XIa inhibitor for acute care, with a primary goal for 2026 to optimize its formulation for complex cardiac surgery.

Sep 30, 2025, 7:30 PM

Get instant answers from SEC filings, earnings calls & more

Cadrenal Therapeutics (CVKD)